Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Positioning immunotherapies in the changing paradigm of myeloma treatment

Meral Beksac • 1 Sep 2020
EBMT 2020
Multiple Myeloma Antibodies Belantamab mafodotin BiTEs CAR-T

Meral Beksac, MD, Ankara University, Ankara, Turkey, explores how to sequence immunotherapies in the evolving treatment landscape of multiple myeloma, including the use of anti-CD38 monoclonal antibodies at diagnosis which has shown to improve prognosis, as well as bi-specific antibodies, antibody-drug conjugates and CAR T-cells targeting BCMA. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meral Beksac

3:36
Ex vivo expanded NK cells for hematological cancer immunotherapy
Meral Beksac • 11 Dec 2023
3:52
EMN19: Dara-VCd in patients with multiple myeloma and extramedullary disease
Meral Beksac • 12 Dec 2023
2:16
The value of the early relapse EBMT score in multiple myeloma
Meral Beksac • 28 Sep 2023
1:30
Exploring the role of upfront autoSCT in multiple myeloma
Meral Beksac • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals